Trials / Completed
CompletedNCT00277823
Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 480 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DVS-SR 50 mg | |
| DRUG | DVS-SR 100 mg | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-02-01
- Completion
- 2007-01-01
- First posted
- 2006-01-16
- Last updated
- 2007-12-28
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00277823. Inclusion in this directory is not an endorsement.